Solid Dispersion of Oxeglitazar in PVP K17 and Poloxamer 407 by Supercritical Antisolvent and Coevaporation Methods

Majerik, V. and Horváth, Géza and Charbit, G. and Badens, E. and Szokonya, L. and Bosc, N. and Teillaud, E. (2006) Solid Dispersion of Oxeglitazar in PVP K17 and Poloxamer 407 by Supercritical Antisolvent and Coevaporation Methods. HUNGARIAN JOURNAL OF INDUSTRY AND CHEMISTRY, 34. pp. 41-49. ISSN 0133-0276

Preview

Text 110-ArticleText-101-1-10-20121005.pdf Download (1MB) | Preview

Abstract

The objective of this work was to improve the dissolution rate and aqueous solubility of oxeglitazar. Solid dispersions of oxeglitazar in PVP K17 (polyvinilpyrrolidone) and Poloxamer 407 (polyoxyethylene-polyoxypropylene block copolymer) were prepared by supercritical antisolvent (SAS) and coevaporation (CoE) methods. Drug-carrier formulations were characterized by powder X-ray diffraction, Fourier transform infrared spectroscopy, scanning electron microscopy, gas chromatography, UV/VIS spectroscopy and in vitro dissolution tests. The highest dissolution rate (nearly 3-fold higher than raw drug) was achieved by preparation of drug/PVP K17 coevaporate. Oxeglitazar/PVP K17 solid dispersions were stabilized by hydrogen bonding but contained higher amount of residual DCM than Poloxamer 407 formulations regardless of the method of preparation. SAS prepared oxeglitazar/Poloxamer 407 dissolved more than two times faster than raw drug. However, unlike PVP K17, Poloxamer 407 did not form a single phase amorphous solid solution with oxeglitazar which has been manifested in higher degrees of crystallinity, too. Among the two techniques, evaluated in this work, conventional coevaporation resulted in higher amorphous content but SAS reduced residual solvent content more efficiently.

Actions (login required)

Edit Item